\-\ Texto\\:\\ \ \(0\)\
\-\ afebrile\\.\\ vss\\.\ \(0\)\
\-\ abdomen\\:\\ soft\\,\\ nontender\\ to\\ palpation\\.\ \(0\)\
\-\ 1\\)\\ cystectomy\\ and\\ close\\ interval\\ follow\\ up\\ for\\ recurrence\\ surveillance\\.\ \(0\)\
\-\ 1\\)\\ not\\ pictured\\:\\ noncontrast\\-enhanced\\ ct\\ abdomen\\/pelvis\\.\\ no\\ nephroureterolithiasis\\.\\ no\\ hydronephrosis\\.\\ soft\\ tissue\\ filling\\ defects\\ in\\ the\\ bladder\\ \\-\\ 1\\)\\ left\\ lateral\\ wall\\,\\ broad\\-based\\ mass\\,\\ 2\\)\\ trigone\\ filling\\ defect\\.\\ \ \(0\)\
\-\ 2\\)\\ status\\ post\\ iv\\ contrast\\:\ \(0\)\
\-\ a\\)\\ \\(2\\)\\ enhancing\\ bladder\\ masses\\.\ \(1\)\
\-\ b\\)\\ symmetric\\ enhancement\\ of\\ normal\\-sized\\ kidneys\\.\\ no\\ hydronephrosis\\.\\ no\\ concomitant\\ upper\\ tract\\ filling\\ defects\\.\ \(0\)\
\-\ transitional\\ cell\\ cancer\\ of\\ bladder\ \(0\)\
\-\ 1\\)\\ \\ urothelial\\ cell\\ tumor\\:\\ transitional\\ cell\\ carcinoma\ \(0\)\
\-\ 2\\)\\ \\ urothelial\\ cell\\ tumor\\:\\ squamous\\ cell\\ carcinoma\ \(0\)\
\-\ 3\\)\\ \\ urothelial\\ cell\\ tumor\\:\\ primary\\ adenocarcinoma\ \(0\)\
\-\ 4\\)\\ \\ metastatic\\ disease\ \(0\)\
\-\ 5\\)\\ \\ benign\\ bladder\\ tumor\\ types\\ ie\\ leiomyoma\ \(0\)\
\-\ 6\\)\\ \\ fungus\\ ball\ \(0\)\
\-\ 7\\)\\ \\ hematoma\ \(0\)\
\-\ 8\\)\\ \\ foreign\\ body\ \(0\)\
\-\ 9\\)\\ \\ enlarged\\ prostate\ \(0\)\
\-\ 10\\)\\ \\ ureterocoele\ \(0\)\
\-\ 11\\)\\ urethral\\ diverticulum\\ \\(\\"female\\ prostate\\"\\)\ \(0\)\
\-\ 12\\)\\ cystitis\\ glandularis\ \(0\)\
\-\ 13\\)\\ schistosomiasis\ \(0\)\
\-\ 60\\ year\\ old\\ male\\ presents\\ with\\ right\\ flank\\ pain\\ and\\ frank\\ hematuria\\.\ \(1\)\
\-\ the\\ patient\\ has\\ a\\ typical\\ profile\\ in\\ terms\\ of\\ age\\ and\\ gender\\.\\ also\\,\\ his\\ presentation\\ is\\ consistent\\ though\\ nonspecific\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ urothelial\\:\\ 0\\.09348708130582468\ \(0\)\
\-\ \\)\\:\\ 0\\.07510923074876895\ \(0\)\
\-\ bladder\\:\\ 0\\.06638106972725415\ \(0\)\
\-\ cell\\:\\ 0\\.06626528358607138\ \(0\)\
\-\ transitional\\:\\ 0\\.050066980722587445\ \(0\)\
\-\ filling\\:\\ 0\\.04938143564041626\ \(0\)\
\-\ prostate\\:\\ 0\\.04343399334880806\ \(0\)\
\-\ noncontrast\\-enhanced\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ nephroureterolithiasis\\:\\ 0\\.042179513990270326\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.041192908300953575\ \(0\)\
\-\ 1\\:\\ 0\\.03891533718583171\ \(0\)\
\-\ ureterocoele\\:\\ 0\\.03886302030338063\ \(0\)\
\-\ glandularis\\:\\ 0\\.03886302030338063\ \(0\)\
\-\ tumor\\:\\ 0\\.03812884787771887\ \(0\)\
\-\ defects\\:\\ 0\\.03756142866741382\ \(0\)\
\-\ 2\\:\\ 0\\.03521731093800088\ \(0\)\
\-\ pictured\\:\\ 0\\.033606502175782024\ \(0\)\
\-\ normal\\-sized\\:\\ 0\\.033606502175782024\ \(0\)\
\-\ cystectomy\\:\\ 0\\.03286893911440758\ \(0\)\
\-\ \\:\\:\\ 0\\.03244808084183728\ \(0\)\
\-\ trigone\\:\\ 0\\.030290008488892333\ \(0\)\
\-\ schistosomiasis\\:\\ 0\\.030290008488892333\ \(0\)\
\-\ fungus\\:\\ 0\\.02891353924271156\ \(0\)\
\-\ cystitis\\:\\ 0\\.028091289209569655\ \(0\)\
\-\ broad\\-based\\:\\ 0\\.0278458667483852\ \(0\)\
\-\ gender\\:\\ 0\\.027389837179943456\ \(0\)\
\-\ abdomen\\/pelvis\\:\\ 0\\.026973514802002642\ \(0\)\
\-\ vss\\:\\ 0\\.026778194254058838\ \(0\)\
\-\ concomitant\\:\\ 0\\.026590535339449835\ \(0\)\
\-\ ie\\:\\ 0\\.026590535339449835\ \(0\)\
\-\ profile\\:\\ 0\\.026590535339449835\ \(0\)\
\-\ terms\\:\\ 0\\.02640995960747449\ \(0\)\
\-\ urethral\\:\\ 0\\.02559704555582187\ \(0\)\
\-\ surveillance\\:\\ 0\\.025449812739234533\ \(0\)\
\-\ ball\\:\\ 0\\.02465051089874092\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.024073343493053765\ \(0\)\
\-\ frank\\:\\ 0\\.023274041652560144\ \(0\)\
\-\ carcinoma\\:\\ 0\\.02317634133986475\ \(0\)\
\-\ nonspecific\\:\\ 0\\.021036735962535406\ \(0\)\
\-\ nontender\\:\\ 0\\.020979433613029588\ \(0\)\
\-\ types\\:\\ 0\\.02086684750101909\ \(0\)\
\-\ foreign\\:\\ 0\\.020145206880279456\ \(0\)\
\-\ interval\\:\\ 0\\.020050457467379074\ \(0\)\
\-\ squamous\\:\\ 0\\.020003777204482594\ \(0\)\
\-\ close\\:\\ 0\\.01995754796567046\ \(0\)\
\-\ soft\\:\\ 0\\.019913174775057895\ \(0\)\
\-\ diverticulum\\:\\ 0\\.01947648945264712\ \(0\)\
\-\ hematuria\\:\\ 0\\.019393992771142305\ \(0\)\
\-\ b\\:\\ 0\\.0192728549338969\ \(0\)\
\-\ flank\\:\\ 0\\.019233147743395965\ \(0\)\
\-\ though\\:\\ 0\\.01896405818204249\ \(0\)\
\-\ afebrile\\:\\ 0\\.018889875471344093\ \(0\)\
\-\ kidneys\\:\\ 0\\.018816825365455155\ \(0\)\
\-\ 11\\:\\ 0\\.01870929973936875\ \(0\)\
\-\ symmetric\\:\\ 0\\.01867398822119831\ \(0\)\
\-\ 13\\:\\ 0\\.018467422805575298\ \(0\)\
\-\ tract\\:\\ 0\\.018110433026670154\ \(0\)\
\-\ recurrence\\:\\ 0\\.017836947792986193\ \(0\)\
\-\ 60\\:\\ 0\\.017836947792986193\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.0176629399261399\ \(0\)\
\-\ 9\\:\\ 0\\.016901027249897175\ \(0\)\
\-\ 12\\:\\ 0\\.016733963780489386\ \(0\)\
\-\ no\\:\\ 0\\.016467830635479463\ \(0\)\
\-\ typical\\:\\ 0\\.016394481790191373\ \(0\)\
\-\ 7\\:\\ 0\\.015666291286163023\ \(0\)\
\-\ defect\\:\\ 0\\.015305011130621658\ \(0\)\
\-\ 8\\:\\ 0\\.015287643819374872\ \(0\)\
\-\ iv\\:\\ 0\\.014920693480675089\ \(0\)\
\-\ status\\:\\ 0\\.014594867565462456\ \(0\)\
\-\ hematoma\\:\\ 0\\.01455008075800043\ \(0\)\
\-\ benign\\:\\ 0\\.014110288837479432\ \(0\)\
\-\ presentation\\:\\ 0\\.014083256624359245\ \(0\)\
\-\ enlarged\\:\\ 0\\.013950340049684241\ \(0\)\
\-\ masses\\:\\ 0\\.013821016258354484\ \(0\)\
\-\ 10\\:\\ 0\\.013782891044722058\ \(0\)\
\-\ palpation\\:\\ 0\\.013645641532765799\ \(0\)\
\-\ cancer\\:\\ 0\\.013440982126147203\ \(0\)\
\-\ body\\:\\ 0\\.013278773744923849\ \(0\)\
\-\ follow\\:\\ 0\\.012991385033236526\ \(0\)\
\-\ post\\:\\ 0\\.01287480877068083\ \(0\)\
\-\ enhancing\\:\\ 0\\.0128227441764821\ \(0\)\
\-\ age\\:\\ 0\\.012444547012173715\ \(0\)\
\-\ 6\\:\\ 0\\.012211101250597484\ \(0\)\
\-\ abdomen\\:\\ 0\\.01211188642533826\ \(0\)\
\-\ primary\\:\\ 0\\.01211188642533826\ \(0\)\
\-\ 5\\:\\ 0\\.01196249005954145\ \(0\)\
\-\ wall\\:\\ 0\\.011842866604013139\ \(0\)\
\-\ his\\:\\ 0\\.011784158027018812\ \(0\)\
\-\ 4\\:\\ 0\\.01139221007262701\ \(0\)\
\-\ up\\:\\ 0\\.010994483976335996\ \(0\)\
\-\ enhancement\\:\\ 0\\.010959276392933186\ \(0\)\
\-\ metastatic\\:\\ 0\\.010292389490986077\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.010048493003023047\ \(0\)\
\-\ consistent\\:\\ 0\\.01002535056857035\ \(0\)\
\-\ upper\\:\\ 0\\.009866413901285733\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.009855260775034656\ \(0\)\
\-\ tissue\\:\\ 0\\.009691010471065041\ \(0\)\
\-\ 3\\:\\ 0\\.00957404558232794\ \(0\)\
\-\ contrast\\:\\ 0\\.009152036778985193\ \(0\)\
\-\ lateral\\:\\ 0\\.008835732275715552\ \(0\)\
\-\ \\-\\:\\ 0\\.00876425099860461\ \(0\)\
\-\ female\\:\\ 0\\.008405551538027911\ \(0\)\
\-\ presents\\:\\ 0\\.008352365050277156\ \(0\)\
\-\ also\\:\\ 0\\.008060380830957661\ \(0\)\
\-\ has\\:\\ 0\\.0076779902894463055\ \(0\)\
\-\ male\\:\\ 0\\.007393327932475948\ \(0\)\
\-\ \\(\\:\\ 0\\.006912552404247469\ \(0\)\
\-\ disease\\:\\ 0\\.0066829547426588715\ \(0\)\
\-\ not\\:\\ 0\\.005908223309770025\ \(0\)\
\-\ ct\\:\\ 0\\.005719156236325564\ \(0\)\
\-\ mass\\:\\ 0\\.005686416301184519\ \(0\)\
\-\ \\,\\:\\ 0\\.005181053885498323\ \(0\)\
\-\ pain\\:\\ 0\\.004993340514501123\ \(0\)\
\-\ left\\:\\ 0\\.004574666360157487\ \(0\)\
\-\ year\\:\\ 0\\.004574666360157487\ \(0\)\
\-\ right\\:\\ 0\\.004314027316317783\ \(0\)\
\-\ old\\:\\ 0\\.004186289937139974\ \(0\)\
\-\ patient\\:\\ 0\\.004098525985245875\ \(0\)\
\-\ in\\:\\ 0\\.004032509379332583\ \(0\)\
\-\ a\\:\\ 0\\.0037952134145320692\ \(0\)\
\-\ for\\:\\ 0\\.003488555735132608\ \(0\)\
\-\ is\\:\\ 0\\.0026903864994484478\ \(0\)\
\-\ and\\:\\ 0\\.0025838613262997865\ \(0\)\
\-\ \\.\\:\\ 0\\.002547813595503321\ \(0\)\
\-\ to\\:\\ 0\\.0020433880786745752\ \(0\)\
\-\ of\\:\\ 0\\.001672303360736676\ \(0\)\
\-\ the\\:\\ 0\\.0013229596622356535\ \(0\)\
\-\ with\\:\\ 0\\.0005598285937315298\ \(0\)\
